Joincare(SH:600380) Zheng Quan Shi Bao Wang·2025-12-12 03:40Group 1 - The core point of the article is that Health元 has successfully launched its innovative drug, Marpasisavir capsules (Yilikan), for flu treatment in China, which allows for "one-time oral treatment" [1] - The drug's development cycle was significantly shortened to two years, compared to the typical 6-8 years for flu drugs, due to the company's early investment in an AI-assisted drug design platform [1] - Health元 has built a strong CMC (Chemistry, Manufacturing, and Control) capability over ten years, enabling a rapid internal process for drug development and production, achieving scale in less than half the industry average time [1] Group 2 - In Phase III clinical trials, the median time for symptom relief in the Yilikan group was significantly shorter by 27.0 hours compared to the placebo group (P<0.0001) [2] - The drug showed particularly strong efficacy in patients with type B influenza, with a symptom relief time reduced by 31.0 hours compared to the placebo (P<0.05) [2] - Yilikan demonstrated good efficacy in adolescents with no serious adverse events reported, maintaining clear effectiveness against both type A and type B influenza, and enhancing treatment convenience and compliance with a single oral dose [2]